Nanoparticle Therapeutics

Production Technologies, Types of Nanoparticles, and Regulatory Aspects

1st Edition - November 6, 2021
Imprint: Academic Press
Editors: Prashant Kesharwani, Kamalinder K. Singh
Language: English
Paperback ISBN:
9 7 8 - 0 - 1 2 - 8 2 0 7 5 7 - 4
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 0 9 1 8 - 9

Nanoparticle therapeutics: Production Technologies, Types of Nanoparticles, and Regulatory Aspects employs unique principles for applications in cell-based therapeutics, diagnosti… Read more

Purchase options

World Book Day Celebration!

Save up to 30% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Nanoparticle therapeutics: Production Technologies, Types of Nanoparticles, and Regulatory Aspects employs unique principles for applications in cell-based therapeutics, diagnostics and mechanistics for the study of organ physiology, disease etiology and drug screening of advanced nanoparticles and nanomaterials. The book focuses on the extrapolation of bioengineering tools in the domain of nanotechnology and nanoparticles therapeutics, fabrication, characterization and drug delivery aspects. It acquaints scientists and researchers on the experiential and experimental aspects of nanoparticles and nanotechnology to equip their rational application in various fields, especially in differential diagnoses and in the treatment of diverse diseased states.

This complete resource provides a holistic understanding of the principle behind formation, characterization, applications, regulations and toxicity of nanoparticles employing myriad principles of nanotechnology. Investigators, pharmaceutical researchers, and advanced students working on technology advancement in the areas of designing targeted therapies, nanoscale imaging systems and diagnostic modalities in human diseases where nanoparticles can be used as a critical tool for technology advancement in drug delivery systems will find this book useful.

Cover image
Title page
Table of Contents
Copyright
Contributors
Preface
Part 1: Synthesis and characterization of NP for drug delivery
Chapter 1: Nanoparticle technologies: Recent state of the art and emerging opportunities
Abstract
Acknowledgment
1: Introduction
2: Dimensional classification of nanoparticles
3: Nanoparticle material types
4: Nanoparticle production technologies
5: Characterization of nanoparticles
6: Applications of nanotechnology
7: Conclusions
References
Chapter 2: Fabrication design, process technologies, and convolutions in the scale-up of nanotherapeutic delivery systems
Abstract
1: Introduction
2: Liposomes as nanoplatform
3: Nanocrystals and nanosuspensions as nanoplatforms
4: Nanoparticles as nanoplatform
5: Supramolecular drug delivery system as nanoplatform
6: Conclusions
References
Chapter 3: In vitro physicochemical characterization of nanocarriers: a road to optimization
Abstract
Acknowledgment
1: Introduction
2: Classification of nanocarriers
3: Characterization of nanocarriers
4: Regulatory and safety aspects of nanocarriers
5: Conclusions and perspectives
References
Chapter 4: Surface engineering of nanoparticles for imparting multifunctionality
Abstract
Acknowledgments
1: Introduction
2: Need of surface engineering in drug delivery
3: Types of targeting moieties
4: Methods of surface engineering of nanoparticles
5: Surface engineered nanoparticles in targeted therapy
6: Surface engineered nanoparticles in diagnosis
7: Surface engineered nanoparticles in theranostic approaches
8: Conclusion
References
Chapter 5: Biofate and cellular interactions of lipid nanoparticles
Abstract
Acknowledgments
1: Introduction
2: Passive and active targeting
3: Lipid-based nanoparticles for drug targeting and delivery
4: Toxicity assessment of lipid nanoparticles
5: Conclusions and perspectives
References
Chapter 6: Cellular interactions of nanoparticles within the vasculature
Abstract
1: Introduction
2: Types of nanoparticles for drug delivery
3: Cellular uptake of nanoparticles
4: Targeted drug delivery to vascular cells using nanoparticles
References
Chapter 7: Pharmacokinetics and in vivo evaluation of nanoparticles
Abstract
1: Introduction
2: Pharmacokinetics
3: PK of drugs per se and encapsulated drugs in nanoparticles
4: Parameters influencing PK of nanoparticles
5: Role of blood proteins in clearance kinetics
6: In vivo toxicological evaluations of nanoparticles
7: Physiology-based pharmacokinetics
8: Pharmacodynamics
9: Toxicity in cell-based targets and animal models
10: Aspects of particle duration in the circulation
11: Enhanced permeation and retention and strategies
12: Conclusion
References
Part 2: Application of nanoparticles in drug delivery
Chapter 8: Biodegradable self-assembled nanocarriers as the drug delivery vehicles
Abstract
1: Introduction
2: Evolution of self-assembly
3: The chemistry behind self-assembled systems
4: Classifications of self-assembled systems
5: Preparation of self-assembled nanocarriers
6: Biomedical applications of self-assembled system
7: Future prospects
References
Chapter 9: Albumin nanoparticles—A versatile and a safe platform for drug delivery applications
Abstract
1: Introduction
2: Human serum albumin (HSA) structure and binding sites
3: Albumin nanocarriers—Synthesis, preparation methods, and lyophilization
4: Types of albumin nanocarriers
5: Surface modification and targeting of albumin nanoparticles
6: Biomedical applications of albumin nanocarriers
7: Conclusion
References
Chapter 10: Silver nanoparticles for biomedical applications
Abstract
1: Introduction
2: Properties
3: Synthesis of silver nanoparticles
4: Characterization of the nanoparticles
5: Biomedical applications of silver nanoparticles
6: Conclusion and future prospective
References
Chapter 11: Synthesis of silica nanoparticles for biological applications
Abstract
1: Introduction
2: Overview of biomedical applications of silica nanoparticles
3: Silica nanoparticle synthesis
4: Shelf-life assessment of nanoparticles
5: The influence of silica nanoparticles on biological systems
6: Strategies to improve the biocompatibility of nanoparticles in vivo
7: Conclusion
References
Chapter 12: Advances in nanocrystals as drug delivery systems
Abstract
1: Introduction
2: Formulation space
3: Production of nanocrystals
4: Formulation of nanosuspension into oral solid dosage forms (OSDs)
5: In vitro in vivo correlation (IVIVC)
6: Applications of nanocrystals in other routes of administration
7: Functionalization of drug nanocrystals
8: Products in market
9: Conclusions and future prospects
References
Chapter 13: Superparamagnetic iron oxide nanoparticles (SPIONs) as therapeutic and diagnostic agents
Abstract
1: Introduction to magnetism and magnetic materials
2: Synthesis and characterization
3: Size, shape, surface charge of SPIONs, and their characterization
4: Applications of SPIONs as theranostic (therapeutic and diagnostics) agents in nanomedicine
5: SPIONs and surface-modified SPIONs in therapy and diagnosis for various diseases
6: Commercial SPIONs, toxicity, and regulatory aspects
7: Conclusions and future perspectives
References
Chapter 14: Bio-inspired nanoparticles as drug delivery vectors
Abstract
1: Introduction
2: Biomimicry lessons from natural systems
3: Bio-responsive synthetic nanocarriers for drug delivery
4: Biomimetic hybrid nanoparticulate systems
5: Clinical trials
6: Conclusions
References
Chapter 15: Radioactive nanoparticles and their biomedical application in nanobrachytherapy
Abstract
1: Introduction
2: Radiation concepts
3: Necessary paths to develop nanobrachytherapy
4: Conclusion
References
Part 3: Environmental and regulatory aspects
Chapter 16: Regulatory pathways and federal perspectives on nanoparticles
Abstract
1: Introduction
2: Management of human health and environmental risks
3: Regulatory considerations on nanotechnology
4: International laws on regulation of nanopharmaceutical products
5: Regulation on technical aspects of nanotechnology
6: The US FDA's policies and practices: Product-focused and science-based
7: US FDA's risk evaluation and risk mitigation strategy in nanotechnology
8: US FDA 21st century initiatives and current nanotechnology regulations
9: ISO standards on nanotechnologies
10: FDA's critical path initiative for nanotechnology product regulations
11: Other global regulatory agency initiatives
12: COVID-19-related guidance documents
13: Nanoparticle therapeutics—Complex by FDA decree
14: Pandemic, perspectives, professionals, and pathways
15: Chaos to continual improvement—A path to harmonization
16: Awareness and self-authorship
16: Closing thoughts
References
Chapter 17: Fate and potential hazards of nanoparticles in the environment
Abstract
1: Background
2: Exposure of nanoparticles in the environment
3: Fate and behavior of nanoparticles
4: Nanoparticles hazard at individual organism level
5: Nanoparticle hazards at food chain level
6: International guidelines on limiting environmental exposure of nanoparticles
7: Conclusions and future aspects
References
Chapter 18: Biological toxicity of nanoparticles
Abstract
1: Introduction
2: Routes of nanoparticle exposure and its relation to toxic effects
3: Influence of the physicochemical properties on the toxicity
4: Mechanism of biological toxicity
5: Molecular toxicity of nanomedicines
6: Cellular toxicity of nanomedicines
7: Tissue toxicity of nanomedicines
8: Nanoparticle toxicity at different organs
9: Immunological responses to nanomedicines
10: Toxicity of different nanoparticles
11: Future aspects
12: Conclusion
References
Index

Prashant Kesharwani

Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “SERB-Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. His Number of citations is = 26779; h-index = 85; i-10 index = 370 (According to google scholar on March 2025). He has more than 30 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072). He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.

Affiliations and expertise

Assistant Professor, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, 470003, India

Kamalinder K. Singh

Prof Kamalinder K Singh is Professor of Pharmaceutical Technology & Drug Delivery and Research Lead at the School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, United Kingdom and heads the Nanomedicine and Innovative technologies research group within the Faculty of Clinical and Biomedical Sciences and is Healthcare Lead for UCLan Centre of Smarts Materials. With more than 35 years’ experience in academia, Prof Singh has contributed significantly to the field of pharmaceutical technology, drug delivery and nanomedicine through authorship of over 80 research articles, 18 patents, 12 book chapters and 60 monographs. Her pioneering research has led to development of many biocompatible nanoparticle-based platform technologies exploiting to deliver drugs across various biological barriers with application to human health and diseases. Prof Singh serves on International Steering Committee for ‘Handbook of Pharmaceutical Excipients’, joint publication by AAPS, Pharmaceutical Press, and Royal Pharmaceutical Society, Great Britain. She has provided leadership to 35 major funded research projects and is currently managing several research projects funded by National Institute of Health, Academy of Medical Sciences, British Council and UK Foreign Commonwealth and Development Office. She has supervised 30 ECRs and delivered more than 70 keynotes and invited talks at prestigious forums around the globe.

Affiliations and expertise

Professor of Pharmaceutical Technology and Drug Delivery, School of Pharmacy and Biomedical Sciences, Faculty of Clinical and Biomedical Sciences, University of Central Lancashire, Preston, UK

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health